Abstract:LPA activated the NF‐κB signaling pathway via LPA1/3, leading to an increase in CCL2 secretion, which was the main driver in ESCC progression. Background Lysophosphatidic acid (LPA) is a small bioactive lipid which acts as a potent regulator in various tumor progressions through six G‐protein‐coupled receptors (LPA1–LPA6). Our previous study demonstrated that the LPA‐producing enzyme, autotaxin (ATX), was upregulated in esophageal squamous cell carcinoma (ESCC) and ATX high expression levels indicated a poor prognosis. Esophageal squamous cell carcinoma is a type of malignant tumor which originates from epithelial cells. Its progression can be affected by the interaction between cancer cells and normal cells. However, the impact of LPA on the interaction between esophageal epithelial cells and cancer cells in the development of ESCC remains uncertain. Methods MTS and Edu assays were performed to determine ESCC cell proliferation in culture medium (CM) derived from LPA‐stimulated esophageal epithelial cells (Het‐1a). A wound healing assay, transwell migration and an invasion assay were performed to assess the metastatic ability of ESCC cells. Cytokine array analysis was conducted to detect the differentially secreted cytokines in CM. The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were utilized to uncover the pathways and cytokines that are influenced by LPA in ESCC. Immunohistochemical staining was employed to measure the expression of ATX and CCL2 in early‐stage ESCC. Quantitative real‐time PCR, western blot, enzyme‐linked immunosorbent assay and an antibody neutralization assay were employed to measure the mechanism of LPA‐mediated communication between epithelial cells and cancer cells. Results Functional experiments showed that exposing ESCC cancer cells to CM from LPA‐treated Het‐1a results in promoting proliferation, migration, invasion and epithelial–mesenchymal transition processes. Using cytokine array analysis, we discovered that LPA triggers the release of multiple cytokines from epithelial cells. After screening of the TCGA and GEO databases, CCL2 was identified and found to be correlated with ATX expression in ESCC. Furthermore, CCL2 levels in both mRNA expression and secretion were observed to be upregulated in epithelial cells upon stimulation with LPA. Blocking CCL2 effectively reduced the pro‐migration influence of CM derived from LPA‐treated Het‐1a. Mechanism studies have demonstrated that LPA activated the NF‐κB signaling pathway through LPA1/3, ultimately causing an increase in CCL2 expression and secretion in Het‐1a. Conclusions Our findings, taken together, demonstrate that CM from LPA‐treated esophageal epithelial cells plays a significant role in promoting the progression of ESCC, with CCL2 acting as the primary regulator.

Anti-PAI-1 Monoclonal Antibody Inhibits the Metastasis and Growth of Esophageal Squamous Cell Carcinoma

Targeting p21-activated kinase 1 inhibits growth and metastasis via Raf1/MEK1/ERK signaling in esophageal squamous cell carcinoma cells

Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance

High‐throughput membrane‐anchored proteome screening reveals PIEZO1 as a promising antibody‐drug target for human esophageal squamous cell carcinoma

Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis

Anti-TMEM16A Monoclonal Antibody Inhibits the Growth and Metastasis of Esophageal Squamous Cell Carcinoma

PAI-1 derived from cancer-associated fibroblasts in esophageal squamous cell carcinoma promotes the invasion of cancer cells and the migration of macrophages

Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1

Co-targeting TMEM16A with a Novel Monoclonal Antibody and EGFR with Cetuximab Inhibits the Growth and Metastasis of Esophageal Squamous Cell Carcinoma.

Anti-PD1/PDL1 Antibodies Plus Chemotherapy As First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma

Plasminogen Activator Inhibitor-1 in Cancer Research.

PTIP Inhibits Cell Invasion in Esophageal Squamous Cell Carcinoma via Modulation of EphA2 Expression

Fully human chitinase-3 like-1 monoclonal antibody inhibits tumor growth, fibrosis, angiogenesis, and immune cell remodeling in lung, pancreatic, and colorectal cancers

Inhibition of PAI‐1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer‐associated fibroblasts

Development of a Specific Aptamer‐Modified Nano‐System to Treat Esophageal Squamous Cell Carcinoma

Dual Effects of an Anti-Cd147 Antibody for Esophageal Cancer Therapy

LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma

Preventive Treatment with PD-1 Antibody Increases Tissue-resident Memory T Cells Infiltration and Delays Esophageal Carcinogenesis

Lysophosphatidic acid promotes ESCC progression by increasing the level of CCL2 secreted by esophageal epithelial cells

Plasminogen Activator Inhibitor 1 Promotes Immunosuppression in Human Non-Small Cell Lung Cancers by Enhancing TGF-Β1 Expression in Macrophage

Apatinib Inhibits Tumor Progression and Promotes Antitumor Efficacy of Cytotoxic Drugs in Esophageal Squamous Cell Carcinoma.